Ondřej Škoda

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Scott E. Kasner, Balakumar Swaminathan, Pablo M. Lavados et al. · The Lancet Neurology · 2018 · 178 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Global Impact of COVID-19 on Stroke Care and IV Thrombolysis

Raul G. Nogueira, Muhammad M. Qureshi, Mohamad Abdalkader et al. · Neurology · 2021 · 154 citations · Full text

Life Sciences, Health Sciences, Global Health +13

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Robert J. Fox, Andrew Chan, Ralf Gold et al. · Neurology Clinical Practice · 2016 · 104 citations · Full text

Life Sciences, Immunology, Pharmacology +14

European Stroke Organisation certification of stroke units and stroke centres

Ulrike Waje‐Andreassen, Darius G. Nabavi, Stefan T. Engelter et al. · European Stroke Journal · 2018 · 63 citations · Full text

Management, Health Services Administration, Quality Management +16